Figure 2. Symptom dynamics during the first two weeks after symptom onset by nirmatrelvir/ritonavir (N/R) treatment and symptom rebound¹ visualized as (A) cumulative probability of symptom resolution², (B) median number of symptoms each day since symptom onset and proportion of patients experiencing symptom rebound, and (C) average daily symptoms after N/R completion (or seven days since symptom onset for untreated group).

Footnote: Participants reported symptoms daily from a list of 15 symptoms including fever (including feeling feverish/chills), cough, sore throat, runny nose, nasal congestion, fatigue (including feeling run down), wheezing, trouble breathing (including shortness of breath), chest tightness (including chest pain), loss of smell or taste, headache, abdominal pain, diarrhea, vomiting, and body aches (including muscle aches).

¹Symptom rebound was defined as an increase of at least two reported symptoms after treatment completion or treatment completion proxy

²Symptom resolution was defined as the first day in which a participant was asymptomatic after which no later symptoms were reported